Which strategy is “best” after myocardial infarction? the beta-blocker strategy plus implantable cardioverter defibrillator trial: rationale and study design

This publication has 50 references indexed in Scilit:

• Can Antiarrhythmic Drugs Survive Survival Trials?
  The American Journal of Cardiology, 1998
• Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studies
  Clinical Cardiology, 1997
• The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
  New England Journal of Medicine, 1996
• Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia
  The American Journal of Cardiology, 1993
• Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction
  New England Journal of Medicine, 1989
• Decreased heart rate variability and its association with increased mortality after acute myocardial infarction
  The American Journal of Cardiology, 1987
• Beta blockade during and after myocardial infarction: An overview of the randomized trials
  Progress in Cardiovascular Diseases, 1985
• The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction.
  Circulation, 1984
• Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction
  New England Journal of Medicine, 1981
• QT interval prolongation as predictor of sudden death in patients with myocardial infarction.
  Circulation, 1978